About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix (NASDAQ: SNGX) Reports Strong Clinical Results from Compatibility Study of HyBryte as a Treatment for Cutaneous T-Cell Lymphoma

By: Spotlight Growth

Soligenix, Inc. (NASDAQ: SNGX) is engaged as a late-stage biopharmaceutical company that is focused on the research, development and commercialization of products to treat rare diseases. Shares of the biopharma company are skyrocketing 111% through early trading on Thursday, May 4, 2023. Over the past three months, Soligenix has seen average daily volume of 42,640 shares. However, volume of 27.86 million shares or dollar volume of around $89.43 million, has already exchanged hands through early trading.

Shares of Soligenix are soaring after the company announced positive results from a compatibility study (protocol HPN-CTCL-02) of HyBryte™ (synthetic hypericin sodium) for the treatment of cutaneous T-cell lymphoma (CTCL). The study involved using the Daavlin Series 7 visible light device, which recently received FDA 510(k) clearance. The open-label study enrolled nine patients for an eight-week HyBryte™ treatment, with treatment response assessed at week 10 using the Composite Assessment of Index Lesion Severity (CAILS) score.

The study aimed to confirm that any light device producing visible light with an appropriate and consistent wavelength (500 to 650 nm) was suitable for HyBryte™ use and to extend the pharmacokinetic profile using a recently developed, more sensitive hypericin assay. The efficacy demonstrated in the study strongly supports the results of the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study. The treatment response data showed 22% improvement after eight weeks of twice-weekly HyBryte™ therapy, consistent with the FLASH trial’s results. All patients experienced improvements in their cumulative CAILS scores (average improvement of 36.4%, range 8 to 100%).

Results in individual lesions showed that 25.9% of the index lesions had at least a 50% improvement in their CAILS score, and 14.8% of the index lesions were completely resolved after only eight weeks of treatment. Systemic exposure and cardiac output measurements demonstrated extremely low and limited levels of systemic hypericin detected in the blood and no observable impact on normal sinus rhythm, reinforcing HyBryte™’s safety.

Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigator for the compatibility study, expressed excitement about working with Soligenix and making HyBryte™ available to patients. He anticipates continuing collaboration with Soligenix to further advance the HyBryte™ program and provide patients with this much-needed treatment option.

“These results reinforce the positive HyBryte™ data from the FLASH study. Important corporate objectives for the study were to replicate results previously observed in the FLASH study, while using finished drug product manufactured by our proposed commercial contract manufacturer and activated using a commercially viable light device,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “We look forward to continuing to work with Dr. Poligone and all of our committed clinical investigators to make HyBryte™ available to this underserved orphan patient population.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Soligenix (NASDAQ: SNGX) Reports Strong Clinical Results from Compatibility Study of HyBryte as a Treatment for Cutaneous T-Cell Lymphoma appeared first on Spotlight Growth.

More News

View More
PayPal Stock: Why Wall Street May Be Undervaluing This Giant
Via MarketBeat
Topics Economy
Tickers PYPL
Why Vertical Aerospace Could Lead the eVTOL Market by 2028
Via MarketBeat
Tickers EVTL VTOL
Is Draganfly's Army Partnership a Game-Changer for Investors?
Via MarketBeat
Tickers DPRO
3 Auto Stocks to Watch as EV and Hybrid Demand Shifts
Via MarketBeat
Topics Economy Stocks World Trade
Tickers F GM TSLA
4 Stocks Set to Benefit From the PDT Rule Change
Via MarketBeat
Topics Regulatory Compliance
Tickers HOOD IBKR SCHW TSLA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.